RNN Entry 1/29 1.0078
From companies website about lead drug
Archexin®, a potential best-in-class compound with FDA orphan designation for the treatment of refractory cancers in various organs including the kidneys, pancreas and ovaries. In contrast to conventional chemotherapy, Archexin® specifically blocks the production of Akt-1, a molecule that plays a central role in the uncontrolled growth of tumor mass. Therefore, Archexin® may be able to replace the current standard cancer therapy with improved efficacy and tolerability.
Archexin has completed a Phase I clinical trial in patients with solid tumors and was shown to be safe and well tolerated with predicted pharmacokinetics. In a Phase IIa trial in patients with advanced pancreatic cancer, Archexin paired with with gemcitabine was shown to be safe and well tolerated. The combination of the two drugs demonstrated a preliminary signal of efficacy with a median survival of 9.1 months, compared to the historical survival data of 5.65 months (Burris et al., 1997, J. Clin Oncol 15:2403) for standard single agent gemcitabine therapy. Rexahn plans to initiate a Phase IIa clinical trial in the fourth quarter of 2013.
Watch your thoughts; they become words.
Watch your words; they become actions.
Watch your actions; they become habits.
Watch your habits; they become character.
Watch your character; it becomes your destiny.
